- Home
- NTIP vs ACXP Comparison
NTIP vs ACXP Comparison
Compare NTIP & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- ACXP
- Stock Information
- Founded
- NTIP 1990
- ACXP 2017
- Country
- NTIP United States
- ACXP United States
- Employees
- NTIP N/A
- ACXP N/A
- Industry
- NTIP Multi-Sector Companies
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- ACXP Health Care
- Exchange
- NTIP Nasdaq
- ACXP Nasdaq
- Market Cap
- NTIP 28.6M
- ACXP 8.4M
- IPO Year
- NTIP 1998
- ACXP 2021
- Fundamental
- Price
- NTIP $1.25
- ACXP $0.49
- Analyst Decision
- NTIP
- ACXP Strong Buy
- Analyst Count
- NTIP 0
- ACXP 2
- Target Price
- NTIP N/A
- ACXP $10.00
- AVG Volume (30 Days)
- NTIP 13.9K
- ACXP 18.6M
- Earning Date
- NTIP 08-11-2025
- ACXP 08-08-2025
- Dividend Yield
- NTIP 8.00%
- ACXP N/A
- EPS Growth
- NTIP N/A
- ACXP N/A
- EPS
- NTIP N/A
- ACXP N/A
- Revenue
- NTIP $250,000.00
- ACXP N/A
- Revenue This Year
- NTIP N/A
- ACXP N/A
- Revenue Next Year
- NTIP N/A
- ACXP N/A
- P/E Ratio
- NTIP N/A
- ACXP N/A
- Revenue Growth
- NTIP N/A
- ACXP N/A
- 52 Week Low
- NTIP $1.16
- ACXP $0.30
- 52 Week High
- NTIP $1.78
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- NTIP 51.66
- ACXP 51.01
- Support Level
- NTIP $1.21
- ACXP $0.46
- Resistance Level
- NTIP $1.30
- ACXP $0.56
- Average True Range (ATR)
- NTIP 0.05
- ACXP 0.10
- MACD
- NTIP -0.00
- ACXP -0.01
- Stochastic Oscillator
- NTIP 64.29
- ACXP 24.27
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.